Selegiline transdermal system

Abstract

Embodiments of the invention relate generally to the field of transdermal delivery and more specifically to transdermal patches containing selegiline base for the treatment of depression, Parkinson's disease, and other nervous system conditions.

What is claimed is: 
     
         1 . A transdermal matrix patch comprising:
 an acrylate copolymer pressure sensitive adhesive which contains vinyl acetate and does not contain any functional groups or crosslinking agents;   polyvinyl pyrrolidone vinyl acetate copolymers (PVP/VA) at a concentration of about 20 wt %; and   a quantity of selegiline,   wherein the transdermal matrix patch is capable of delivering the quantity of selegiline over a period of up to about seven days and at a rate of at least about 12 μg/cm 2 /hour over a period of at least the first 48 hours.   
     
     
         2 . The transdermal matrix patch of  claim 1 , wherein the transdermal patch is capable of delivering the quantity of selegiline at a rate of at least about 16 μg/cm 2 /hour over the period of at least the first 48 hours. 
     
     
         3 . The transdermal matrix patch of  claim 1 , wherein the transdermal patch is capable of delivering the quantity of selegiline at a rate of at least about 24 μg/cm 2 /hour over the period of at least the first 48 hours. 
     
     
         4 . The transdermal matrix patch of  claim 1 , further comprising an enhancer or excipient having a vapor pressure at 20° C. that is higher than 0.2 mm Hg.